title: [A case report of refractory ALK-positive anaplastic large cell lymphoma treated with Brentuximab vedotin].
authors.affiliation: Department of Geriatric Hematology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Z G
authors.initials: ZG
authors.lastname: Cao
authors.affiliation: Department of Geriatric Hematology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Z H
authors.initials: ZH
authors.lastname: Wang
authors.affiliation: Department of Geriatric Hematology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: J Z
authors.initials: JZ
authors.lastname: Sun
authors.affiliation: Department of Geriatric Hematology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: M
authors.initials: M
authors.lastname: Liu
authors.affiliation: Department of Geriatric Hematology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: X Y
authors.initials: XY
authors.lastname: Zhou
authors.affiliation: Department of Biotherapeutics, General Hospital of People's Liberation Army, Beijing 100853, China.
authors.forename: Q M
authors.initials: QM
authors.lastname: Yang
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000079963:Brentuximab Vedotin; D006801:Humans; D018796:Immunoconjugates; D017728:Lymphoma, Large-Cell, Anaplastic; D020794:Receptor Protein-Tyrosine Kinases
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases